Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary
Authors:
- David B. CluckDCDavid B. Cluck
- Daniel B. ChastainDCDaniel B. Chastain
- Milena MurrayMMMilena Murray
- Spencer H. DurhamSpencer H. Durham
- Elias B. ChahineECElias B. Chahine
- Caroline DerrickCDCaroline Derrick
- Julie B. DumondJDJulie B. Dumond
- E. Kelly HesterEHE. Kelly Hester
- Melissa D. JohnsonMJMelissa D. Johnson
- Wesley D. KufelWKWesley D. Kufel
Open Access
- 1 May 2024
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (5) , 354-359
Abstract
Treatment options are currently limited for persons with HIV‐1 (PWH) who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1. Three agents have been approved by the U.S. Food and Drug Administration (FDA) since 2018, representing a significant advancement for this population: ibalizumab, fostemsavir, and lenacapavir. However, there is a paucity of recommendations endorsed by national and international guidelines describing the optimal use (e.g., selection and monitoring after initiation) of these novel antiretrovirals in this population. To address this gap, a modified Delphi technique was used to develop these consensus recommendations that establish a framework for initiating and managing ibalizumab, fostemsavir, or lenacapavir in PWH who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1. In addition, future areas of research are also identified and discussed in the main document.Keywords
This publication has 1 reference indexed in Scilit:
- Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical PharmacyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024